Local Activation and Systemic Dysregulation of T Lymphocytes in Sjogren's Syndrome

被引:6
作者
Busch, Robert [1 ]
Hadjinicolaou, Andreas V. [1 ]
Hall, Frances C. [1 ]
机构
[1] Univ Cambridge, Dept Med, Div Rheumatol, Cambridge CB2 2QQ, England
关键词
Autoimmune disease; cytokines; cytotoxicity; homeostasis; pathophysiology; Sjogren's syndrome; T-cell activation; T lymphocyte subset; LABIAL SALIVARY-GLANDS; NECROSIS-FACTOR-ALPHA; MESSENGER-RNA EXPRESSION; ANTIGEN-PRESENTING CELLS; GROWTH-FACTOR-BETA; RECEPTOR V-ALPHA; PERIPHERAL-BLOOD; EPITHELIAL-CELLS; AUTOIMMUNE EXOCRINOPATHY; MONOCLONAL-ANTIBODIES;
D O I
10.2174/138920112802273092
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
T cells are implicated in both local and systemic pathophysiology of primary Sjogren's syndrome (PSS). Lymphocytic infiltrates in exocrine glands are dominated by CD4+ T cells, some contributing to ectopic lymphoid tissue, others, unusually, exhibiting cytotoxic potential. Cytokine secretion patterns are complex, with Th1 and Th17 components implicated in pathology. Circulating T cells exhibit phenotypes consistent with hyperactivation, cytokine imbalance, and homeostatic alterations; CD4 lymphopenia is recognized as a risk factor for developing lymphoma. Evidence of oligoclonal expansion is found locally and systemically. Functional alterations (e. g. cytokine secretion profile, migratory potential, target cell interactions) are less clearly defined. Attempts at T cell-targeted therapy of PSS have been limited, although therapy targeted at other arms of the immune response may also affect T cells. A better understanding of T-cell dysregulation in PSS is required in order to understand its contribution to disease, aid prognosis, and improve therapeutic interventions aimed at this aspect of the disease.
引用
收藏
页码:2009 / 2021
页数:13
相关论文
共 168 条
[51]  
Halse AK, 1999, SCAND J IMMUNOL, V49, P533
[52]   Immunopathogenesis of primary Sjogren's syndrome:: implications for disease management and therapy [J].
Hansen, A ;
Lipsky, PE ;
Dörner, T .
CURRENT OPINION IN RHEUMATOLOGY, 2005, 17 (05) :558-565
[53]   Effective treatment of a mouse model of Sjogren's syndrome with eyedrop administration of anti-CD4 monoclonal antibody [J].
Hayashi, Y ;
Ishimaru, N ;
Arakaki, R ;
Tsukumo, S ;
Fukui, H ;
Kishihara, K ;
Shiota, H ;
Yasutomo, K ;
Hayashi, Y .
ARTHRITIS AND RHEUMATISM, 2004, 50 (09) :2903-2910
[54]   Mucosal administration of α-fodrin inhibits experimental Sjogren's syndrome autoimmunity [J].
He, Jing ;
Zhao, Jinxia ;
Li, Zhanguo .
ARTHRITIS RESEARCH & THERAPY, 2008, 10 (02)
[55]   Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjogren's syndrome and systemic sclerosis [J].
Hebbar, M ;
Jeannin, P ;
Magistrelli, G ;
Hatron, PY ;
Hachulla, E ;
Devulder, B ;
Bonnefoy, JY ;
Delneste, Y .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2004, 136 (02) :388-392
[56]   Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection [J].
Hellerstein, MK ;
Hoh, RA ;
Hanley, MB ;
Cesar, D ;
Lee, D ;
Neese, RA ;
McCune, JM .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (06) :956-966
[57]   Antibodies to CD4 in primary Sjogren's syndrome [J].
Henriksson, G ;
Manthorpe, R ;
Bredberg, A .
RHEUMATOLOGY, 2000, 39 (02) :142-147
[58]   Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects [J].
Hjelmervik, TOR ;
Petersen, K ;
Jonassen, I ;
Jonsson, R ;
Bolstad, AI .
ARTHRITIS AND RHEUMATISM, 2005, 52 (05) :1534-1544
[59]   An alternative perspective to the immune response in autoimmune exocrinopathy: Induction of functional quiescence rather than destructive autoaggression [J].
Humphreys-Beher, MG ;
Brayer, J ;
Yamachika, S ;
Peck, AB ;
Jonsson, R .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1999, 49 (01) :7-10
[60]  
ICHIKAWA Y, 1991, CLIN EXP RHEUMATOL, V9, P603